e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Risk assessment for tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The influence of a high negative control on the interpretation of QuantiFERON Gold in Tube (QFN) results
W. Ricketts, G. Bothamley (London, United Kingdom)
Source:
Annual Congress 2011 - Risk assessment for tuberculosis
Session:
Risk assessment for tuberculosis
Session type:
Thematic Poster Session
Number:
2663
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Ricketts, G. Bothamley (London, United Kingdom). The influence of a high negative control on the interpretation of QuantiFERON Gold in Tube (QFN) results. Eur Respir J 2011; 38: Suppl. 55, 2663
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
Related content which might interest you:
Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results
Source: Eur Respir J, 50 (4) 1701267; 10.1183/13993003.01267-2017
Year: 2017
Comparison of the accuracy of QuantiFERON TB gold in tube vs QuantiFERON-TB plus
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016
Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection
Source: International Congress 2019 – Tuberculosis: diagnosis and scores
Year: 2019
Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice
Source: Eur Respir J 2009; 33: 812-815
Year: 2009
First evaluation of QuantiFERON-TB Gold Plus performance in contact screening
Source: Eur Respir J 2016; 48: 1411-1419
Year: 2016
Evaluation of QuantiFERON microtube, using 0.9 mL blood, for diagnosing tuberculosis infection
Source: Eur Respir J 2013; 41: 909-916
Year: 2013
A comparison of QuantiFERON-TB Gold In-Tube test and new QuantiFERON-Microtube assay in children suspect of active TB and adults with active TB
Source: Annual Congress 2011 - Tuberculosis in pregnancy and childhood
Year: 2011
The QuantiFERON-TB Gold test at HIV patients
Source: Annual Congress 2010 - Clinical tuberculosis
Year: 2010
The diagnostic efficiency of TB quantiferon gold test in tuberculosis (preeliminary reports)
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008
Effects of corticosteroid treatment on the performance of QuantiFERON Gold In-Tube test in the diagnosis of latent tuberculosis infection
Source: Annual Congress 2010 - Immune responses for the diagnosis of tuberculosis
Year: 2010
Cut-off point for tuberculin skin test (TST) and QuantiFERON (QTF) in the diagnosis of tuberculosis infection (TI) in a study of contacts of tuberculosis (TB)
Source: Annual Congress 2012 - Tuberculosis and immunologic assays
Year: 2012
QuantiFERON-TB® Gold Plus as a potential tuberculosis treatment monitoring tool
Source: Eur Respir J , 49 (3) 1601976; DOI: 10.1183/13993003.01976-2016
Year: 2017
Comparison of tuberculin skin test (TST) and QuantiFERON-TB-Gold in Tube (QFT) in the diagnosis of latent tuberculosis infection (LTBI) in a prospective community study of contacts of tuberculosis (TB)
Source: Annual Congress 2010 - What is new in the diagnosis of tuberculosis?
Year: 2010
Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms
Source: Eur Respir J 2011; 39: 163-171
Year: 2012
Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms
Source: Eur Respir J 2012; 39: 163-171
Year: 2012
Patients with culture positive active tuberculosis but negative "QuantiFERON-TB Gold in Tube Test" (QFT) – A critical view on the cut-off in clinical praxis
Source: Annual Congress 2010 - Immune responses for the diagnosis of tuberculosis
Year: 2010
First independent evaluation of QuantiFERON-TB Plus performance
Source: Eur Respir J 2016; 47:1587-1590
Year: 2016
Evaluation of QuantiFERON TB test (QFT-TB) in detection of children infected with mycobacterium tuberculosis
Source: Annual Congress 2009 - From bench to bedside: diagnosis of tuberculosis
Year: 2009
Performance of two interferon-gamma release assays (T-SPOT.TB and QuantiFERON-TB GOLD In Tube) increase diagnostic yield of tuberculin skin testing for detection of latent tuberculosis in patients with inflammatory bowel disease
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept